Literature DB >> 27408157

Male Andropause : A Myth or Reality.

P R Nandy1, D V Singh2, P Madhusoodanan3, A S Sandhu4.   

Abstract

Male andropause, male climacteric or viropause is a condition in which men suffer from complex symptomatology due to low androgen level with aging. After the age of 40 years testosterone level starts declining and andropause corresponds to the age at which a pathogenic threshold is reached. This review summarizes the etiology, consequences, screening, diagnosis, monitoring of androgen deficiency in aging male (ADAM). The pros and cons of testosterone replacement therapy (TRT) in elderly male have been discussed. Currently oral, transdermal, transbuccal, intramuscular, and subcutaneous implants are available for clinical use. The choice is made by physicians based on therapeutic indication and patient preferences.

Entities:  

Keywords:  Aging male; Andropause; Testosterone replacement therapy

Year:  2011        PMID: 27408157      PMCID: PMC4921612          DOI: 10.1016/S0377-1237(08)80105-0

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  25 in total

Review 1.  Testosterone supplementation in older men: a rational idea whose time has not yet come.

Authors:  S Bhasin; J G Buckwalter
Journal:  J Androl       Date:  2001 Sep-Oct

Review 2.  Androgen replacement therapy in the aging male--a critical evaluation.

Authors:  A Vermeulen
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

Review 3.  Transdermal delivery of drugs for urologic applications: basic principles and applications.

Authors:  Victor W Nitti; Steven Sanders; David R Staskin; Roger R Dmochowski; Peter K Sand; Scott MacDiarmid; Howard I Maibach
Journal:  Urology       Date:  2006-04       Impact factor: 2.649

Review 4.  Andropause: a misnomer for a true clinical entity.

Authors:  A Morales; J P Heaton; C C Carson
Journal:  J Urol       Date:  2000-03       Impact factor: 7.450

Review 5.  ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.

Authors:  B Lunenfeld; F Saad; C E Hoesl
Journal:  Aging Male       Date:  2005-06       Impact factor: 5.892

Review 6.  The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.

Authors:  T Ebert; F Jockenhövel; A Morales; R Shabsigh
Journal:  Eur Urol       Date:  2005-02       Impact factor: 20.096

7.  Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study.

Authors:  A Gray; H A Feldman; J B McKinlay; C Longcope
Journal:  J Clin Endocrinol Metab       Date:  1991-11       Impact factor: 5.958

8.  Validation of a screening questionnaire for androgen deficiency in aging males.

Authors:  J E Morley; E Charlton; P Patrick; F E Kaiser; P Cadeau; D McCready; H M Perry
Journal:  Metabolism       Date:  2000-09       Impact factor: 8.694

9.  Is it andropause? Recognizing androgen deficiency in aging men.

Authors:  Robert S Tan; Shou-Jin Pu
Journal:  Postgrad Med       Date:  2004-01       Impact factor: 3.840

10.  Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.

Authors:  Robert E Gerstenbluth; Prakash N Maniam; Eric W Corty; Allen D Seftel
Journal:  J Androl       Date:  2002 Nov-Dec
View more
  1 in total

1.  Knowledge and Attitude about Andropause Among General Physicians in Shiraz, Iran 2014.

Authors:  Maliheh Abootalebi; Marzieh Kargar; Iran Jahanbin; Alireza Amin Sharifi; Zahra Sharafi
Journal:  Int J Community Based Nurs Midwifery       Date:  2016-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.